ANDA 206120, held by Xiromed. Ethinyl Estradiol; Norethindrone Acetate.
As of Nov 16, 2026, ANDA 206120 (Norethindrone Acetate And Ethinyl Estradiol And Ferrous Fumarate), held by Xiromed, was first approved by FDA on Sep 12, 2017, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 12, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Norethindrone Acetate And Ethinyl Estradiol And Ferrous Fumarate0.02MG;1MG · tablet;oral | Ethinyl Estradiol; Norethindrone Acetate | Discontinued |
| Jun 20, 2025 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 12, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters